Nanoscope Therapeutics Inc.
Stephen Kaminsky is an accomplished professional in genetic medicine and biopharmaceuticals with extensive experience in leadership and research roles. Currently, Stephen serves on the External Oversight Committee for the NIH Blueprint Neurotherapeutics Network for Biologics and holds leadership in the Viral Vector Program at the National Institute for Innovation in Biomanufacturing Biopharmaceuticals. Ongoing contributions include advisory positions at Nanoscope Therapeutics Inc. and Agathos Biologics, along with a long-standing role as Professor of Research and Associate Director of the Gene Therapy Core at Weill Cornell Medical College. Stephen's background includes significant work in immunogen design for HIV-1 at the International AIDS Vaccine Initiative, project direction in protein and analytical chemistry, and establishing viral vector manufacturing facilities while leading innovative gene therapy initiatives for various diseases. Academic credentials include a Ph.D. from Yale University and a BS from Cornell University.
This person is not in any teams
This person is not in any offices
Nanoscope Therapeutics Inc.
1 followers
Nanoscope Therapeutics is advancing gene therapy using light-sensitive molecules and light-assisted gene delivery for giving sight to the millions of blind individuals suffering from retinal degenerative disease, for which no cure exists. Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD. Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells. Update: June, 2021: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b clinical trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with Retinitis Pigmentosa